Senti Biosciences, Inc. - Common Stock SNTI 深 滬
已收盤 12-12 16:00:00 美东时间
1.31
-0.105
-7.42%
華盛通- 最 高1.3699
- 今 開1.35
- 成交量 133.10万股
- 最 低 1.27
- 昨 收 1.415
- 總市值 3426.99万
- 52周最高 5.10
- 市盈率 靜 --
- 換手率 5.09%
- 52周最低 1.26
- 委 比 -9.59%
- 總股本 2616.02万
- 歷史最高 87.70
- 量 比 0.08
- 振 幅 7.06%
- 歷史最低 1.26
- 每 手 1
- 風險率 1.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Market-Moving News for December 9th
XCUR: 176% | Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte colony-stimulating factor for the
12-09 20:21
Senti Biosciences Says FDA Grants Regenerative Medicine Advanced Therapy Designation To SENTI-202 For Treatment Of R/R Hematologic Malignancies, Including AML
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical evidence, and offers
12-09 20:17
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
Leerink Partners Initiates Coverage On Senti Biosciences with Outperform Rating, Announces Price Target of $6
Leerink Partners analyst Jeffrey La Rosa initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Outperform rating and announces Price Target of $6.
11-21 22:34
Senti Biosciences Q3 EPS $(0.69) Misses $(0.56) Estimate
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.56) by 23.21 percent. This is a 89.06 percent increase over losses of $(6.31) per share
11-14 06:02
Senti Biosciences Says SENTI-202 Shows Deep, Durable Remissions In R/R AML With Selective Cancer Killing Ahead Of ASH 2025 Presentations
Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating relapsed/refractory Acute Myeloid
11-03 22:13
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
Senti Biosciences, Inc. announced that its CEO, Timothy Lu, will present at the 9th Annual Genetic Medicines Conference on October 21, 2025. The live presentation will be webcast on the company’s website. Senti Bio, a clinical-stage biotech company, develops next-generation cell and gene therapies using its proprietary Gene Circuit platform to target incurable diseases, with a focus on cancer treatments. The platform aims to enhance precision and...
10-16 13:05
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
